Kennedy Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 13.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,372 shares of the medical research company's stock after purchasing an additional 4,084 shares during the quarter. Kennedy Capital Management LLC's holdings in Thermo Fisher Scientific were worth $17,881,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently added to or reduced their stakes in the company. Scotia Capital Inc. raised its holdings in Thermo Fisher Scientific by 57.3% in the 4th quarter. Scotia Capital Inc. now owns 63,585 shares of the medical research company's stock worth $33,082,000 after purchasing an additional 23,168 shares during the period. CenterBook Partners LP grew its stake in shares of Thermo Fisher Scientific by 273.8% during the 4th quarter. CenterBook Partners LP now owns 1,327 shares of the medical research company's stock valued at $690,000 after acquiring an additional 972 shares during the period. DRW Securities LLC bought a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $1,154,000. APG Asset Management US Inc. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $4,107,000. Finally, Texas Yale Capital Corp. raised its position in shares of Thermo Fisher Scientific by 7.7% during the 4th quarter. Texas Yale Capital Corp. now owns 530 shares of the medical research company's stock valued at $276,000 after purchasing an additional 38 shares during the period. 89.23% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares of the company's stock, valued at $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock valued at $13,106,062 over the last quarter. 0.34% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on TMO shares. Raymond James restated an "outperform" rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Wells Fargo & Company upped their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. UBS Group lifted their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a report on Friday, January 31st. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Finally, Barclays cut their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $647.43.
Get Our Latest Report on Thermo Fisher Scientific
Thermo Fisher Scientific Stock Performance
TMO traded down $9.46 on Tuesday, reaching $439.87. The stock had a trading volume of 1,181,423 shares, compared to its average volume of 1,699,621. The business's 50-day moving average price is $507.90 and its two-hundred day moving average price is $537.62. The company has a market cap of $165.95 billion, a P/E ratio of 26.61, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a 12-month low of $409.85 and a 12-month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.
Thermo Fisher Scientific Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.39%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific's payout ratio is presently 10.41%.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Recommended Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
